These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23518872)

  • 1. Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial.
    Caixeta A; Lansky AJ; Mehran R; Brener SJ; Claessen B; Généreux P; Palmerini T; Witzenbichler B; Guagliumi G; Brodie BR; Dudek D; Fahy M; Dangas GD; Stone GW;
    EuroIntervention; 2013 Jun; 9(2):220-7. PubMed ID: 23518872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of infarct-related artery patency before primary PCI on outcome in patients with ST-segment elevation myocardial infarction: the HORIZONS-AMI trial.
    Rakowski T; Dudek D; Dziewierz A; Yu J; Witzenbichler B; Guagliumi G; Kornowski R; Hartmann F; Lansky AJ; Brener SJ; Mehran R; Stone GW
    EuroIntervention; 2013 Mar; 8(11):1307-14. PubMed ID: 23538158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy.
    Wöhrle J; Merkle N; Kunze M; Cristea E; Mehran R; Rottbauer W; Stone GW
    Catheter Cardiovasc Interv; 2012 Jun; 79(7):1083-9. PubMed ID: 22162175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.
    Parodi G; Antoniucci D; Nikolsky E; Witzenbichler B; Guagliumi G; Peruga JZ; Stuckey T; Dudek D; Kornowski R; Hartmann F; Lansky AJ; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2010 Aug; 3(8):796-802. PubMed ID: 20723849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
    Valgimigli M; Campo G; Malagutti P; Anselmi M; Bolognese L; Ribichini F; Boccuzzi G; de Cesare N; Rodriguez AE; Russo F; Moreno R; Biondi-Zoccai G; Penzo C; Díaz Fernández JF; Parrinello G; Ferrari R
    JACC Cardiovasc Interv; 2011 Jan; 4(1):51-62. PubMed ID: 21251629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials.
    Mehran R; Pocock S; Nikolsky E; Dangas GD; Clayton T; Claessen BE; Caixeta A; Feit F; Manoukian SV; White H; Bertrand M; Ohman EM; Parise H; Lansky AJ; Lincoff AM; Stone GW
    JACC Cardiovasc Interv; 2011 Jun; 4(6):654-64. PubMed ID: 21700252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
    Saltzman AJ; Stone GW; Claessen BE; Narula A; Leon-Reyes S; Weisz G; Brodie B; Witzenbichler B; Guagliumi G; Kornowski R; Dudek D; Metzger DC; Lansky AJ; Nikolsky E; Dangas GD; Mehran R
    JACC Cardiovasc Interv; 2011 Sep; 4(9):1011-9. PubMed ID: 21939942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial.
    Patel MR; Worthley SG; Stebbins A; Dill T; Rademakers FE; Valeti US; Barsness GW; Van de Werf F; Hamm CW; Armstrong PW; Granger CB; Kim RJ
    JACC Cardiovasc Imaging; 2010 Jan; 3(1):52-60. PubMed ID: 20129531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.
    Mehran R; Lansky AJ; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Wong SC; Nikolsky E; Gambone L; Vandertie L; Parise H; Dangas GD; Stone GW;
    Lancet; 2009 Oct; 374(9696):1149-59. PubMed ID: 19717185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors and implications of coronary infarct artery patency at initial angiography in patients with acute myocardial infarction (from the CADILLAC and HORIZONS-AMI Trials).
    Brener SJ; Mehran R; Brodie BR; Guagliumi G; Witzenbichler B; Cristea E; Xu K; Lansky AJ; Stone GW
    Am J Cardiol; 2011 Oct; 108(7):918-23. PubMed ID: 21764028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between attenuated plaque identified by intravascular ultrasound and no-reflow after stenting in acute myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
    Wu X; Mintz GS; Xu K; Lansky AJ; Witzenbichler B; Guagliumi G; Brodie B; Kellett MA; Dressler O; Parise H; Mehran R; Stone GW; Maehara A
    JACC Cardiovasc Interv; 2011 May; 4(5):495-502. PubMed ID: 21596321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombus aspiration in primary percutaneous coronary intervention in high-risk patients with ST-elevation myocardial infarction: a real-world registry.
    Mangiacapra F; Wijns W; De Luca G; Muller O; Trana C; Ntalianis A; Heyndrickx G; Vanderheyden M; Bartunek J; De Bruyne B; Barbato E
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):70-6. PubMed ID: 20578196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial.
    Sanborn TA; Tomey MI; Mehran R; Généreux P; Witzenbichler B; Brener SJ; Kirtane AJ; McAndrew TC; Kornowski R; Dudek D; Nikolsky E; Stone GW
    Catheter Cardiovasc Interv; 2015 Feb; 85(3):371-9. PubMed ID: 25179260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors and prognosis of suboptimal coronary blood flow after primary coronary angioplasty in patients with acute myocardial infarction.
    Cura FA; L'Allier PL; Kapadia SR; Houghtaling PL; Dipaola LM; Ellis SG; Topol EJ; Brener SJ;
    Am J Cardiol; 2001 Jul; 88(2):124-8. PubMed ID: 11448407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of multivessel disease on myocardial perfusion and survival among patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitors.
    De Luca G; Gibson M; Cutlip D; Huber K; Dudek D; Bellandi F; Noc M; Maioli M; Zorman S; Zeymer U; Secco GG; Mesquita Gabriel H; Emre A; Arntz HR; Rakowski T; Gyongyosi M; Hof AW;
    Arch Cardiovasc Dis; 2013 Mar; 106(3):155-61. PubMed ID: 23582677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
    Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
    Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
    Hermanides RS; van Werkum JW; Ottervanger JP; Breet NJ; Gosselink AT; van Houwelingen KG; Dambrink JH; Hamm C; ten Berg JM; van 't Hof AW;
    Catheter Cardiovasc Interv; 2012 May; 79(6):956-64. PubMed ID: 22162050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex-based differences in clinical and angiographic outcomes in patients with ST-elevation myocardial infarction treated with concomitant use of glycoprotein IIb/IIIa inhibitors.
    Kralev S; Hennig O; Lang S; Kälsch T; Borggrefe M; Dempfle CE; Süselbeck T
    Cardiol J; 2010; 17(6):580-6. PubMed ID: 21154260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors.
    De Luca G; Gibson CM; Bellandi F; Noc M; Dudek D; Zeymer U; Arntz HR; Cutlip D; Maioli M; Zorman S; Mesquita Gabriel H; Emre A; Rakowski T; Gyongyosi M; Huber K; Van't Hof AW
    Atherosclerosis; 2009 Nov; 207(1):181-5. PubMed ID: 19426981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of thrombus aspiration on angiographic and clinical outcomes in patients with ST-elevation myocardial infarction.
    Beaudoin J; Dery JP; Lachance P; Bertrand OF; Larose E; Rodés-Cabau J; Noël B; Barbeau G; Proulx G; Nguyen C; Roy L; Gleeton O; Rinfret S; Delarochellière R
    Cardiovasc Revasc Med; 2010; 11(4):218-22. PubMed ID: 20934652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.